Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Abagovomab"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Cancer Management and Research. 11:4119-4128
Background: The number of published randomized clinical trials (RCTs) using targeted maintenance therapy for newly diagnosed epithelial ovarian cancer is increasing. Our objective was to evaluate the comparative effectiveness of each maintenance ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bafcba358d3507d47bdfda60fe1e5b24
https://doi.org/10.2147/cmar.s187119
https://doi.org/10.2147/cmar.s187119
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Srustidhar Das, Surinder K. Batra
Publikováno v:
Cancer Research. 75:4669-4674
CA125, the most widely used ovarian cancer biomarker, was first identified approximately 35 years ago in an antibody screen against ovarian cancer antigen. Two decades later, it was cloned and characterized to be a transmembrane mucin, MUC16. Since t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98ca87da9a6605cc7ab25805a789bfc5
https://doi.org/10.1158/0008-5472.can-15-1050
https://doi.org/10.1158/0008-5472.can-15-1050
Introduction Despite encouraging phase I and II study results, vaccination of ovarian cancer patients with abagovomab – an anti-idiotypic mAb that mimics the ovarian cancer CA125 protein – failed to demonstrate efficacy in the phase III trial nam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69e9e433bda7ed7317423f9be1e8fd34
http://hdl.handle.net/10807/111940
http://hdl.handle.net/10807/111940
Autor:
Alessandra Battaglia, Giovanni Scambia, Alexia Buzzonetti, Andrea Fattorossi, Marco Fossati, Valentina Catzola
Publikováno v:
Cancer Immunology, Immunotherapy. 63:1037-1045
To determine whether abagovomab induces protective immune responses in ovarian cancer patients in first clinical remission. The present analysis is a substudy of monoclonal antibody immunotherapy for malignancies of the ovary by subcutaneous abagovom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34573704b8f0547ab8be5486105dac72
https://doi.org/10.1007/s00262-014-1569-0
https://doi.org/10.1007/s00262-014-1569-0
Autor:
Cristina Goso, Jens Flemming, Christel C. Müller-Goymann, Karsten Gröger, Lena Wolff, Reinhard Schmitz
Publikováno v:
Colloids and Surfaces A: Physicochemical and Engineering Aspects. 339:82-93
This study evaluates the stability of lyophilised aluminium hydroxide adjuvanted vaccine formulations during stress testings at elevated temperatures. Trehalose, dextran, HES, PVP, saccharose and sorbitol were used as excipients to protect both vacci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::757ed56d6aca50e214f5082a27fcb135
https://doi.org/10.1016/j.colsurfa.2009.01.019
https://doi.org/10.1016/j.colsurfa.2009.01.019
Autor:
Jens Flemming, Christel C. Müller-Goymann, Karsten Gröger, Cristina Goso, Reinhard Schmitz, Lena Wolff
Publikováno v:
Vaccine. 27:1834-1840
This study evaluates the forces involved in the adsorption of abagovomab onto an aluminium hydroxide adjuvant in interstitial fluid and the influences of interstitial fluid and its components on this process. Abagovomab is a monoclonal, anti-idiotypi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fc0fe295716427abe073c68d682b6aa
https://doi.org/10.1016/j.vaccine.2009.01.037
https://doi.org/10.1016/j.vaccine.2009.01.037
Autor:
Felix Hilpert, A. du Bois, Rainer Kimmig, C. Jackisch, Antje Belau, Jacobus Pfisterer, Ulrich Canzler, S. Loibl, Jalid Sehouli, Alexander Reuss, Silke Reinartz, V. Heilmann, K. Wollschlaeger
Publikováno v:
Annals of Oncology. 17:1568-1577
Background: Abagovomab is a murine anti-idiotypic antibody against the antigen CA-125 which has been shown to elicit humoral and cellular immune responses against ovarian cancer (oc). Patients and methods: This phase I trial included 36 patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2834515b9efc240171be2ce80b9cda53
https://doi.org/10.1093/annonc/mdl357
https://doi.org/10.1093/annonc/mdl357